Latest News

Category: ASX

See all

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

ASX, Clinical, News,

Telix today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) of using olaratumab to selectively deliver both diagnostic and therapeutic radiation to tumours as a radiopharmaceutical moiety and has produced a candidate for clinical translation. Telix will now progress to first-in-human clinical studies based on these highly...

Read more

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

ASX, Clinical, News,

Telix today announces the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a Phase I study of TLX101 investigational therapy (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in...

Read more

Telix Quarterly Results and Investor Call / Webcast Notification

ASX, News,

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 31 March 2023 on Monday 17 April 2023 at market...

Read more

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

ASX, News,

Telix today announces its financial results for the financial year ended 31 December...

Read more

Telix 2022 Full Year Results and Investor Call / Webcast Notification

ASX, News,

Telix today advises it will release its Full Year Results and Annual Report for the period ended 31 December 2022 on Monday 27 February 2023 at market...

Read more

Notification of Investor Briefing: ASCO-GU ZIRCON Phase III Results Presentation

ASX, News,

Telix advises that Associate Professor Brian Shuch, MD, Director, Kidney Cancer Program, UCLA Institute of Urologic Oncology (Los Angeles, California) and a Principal Investigator in the Phase III ZIRCON study...

Read more

Activities Report and Appendix 4C for December quarter

ASX, News,

Telix today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2022 (Q4 2022). All figures are in AUD$ unless otherwise...

Read more

Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update

ASX, News,

Telix today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9–12 January) in San Francisco. As part of the Company’s presentation (lodged with this announcement), Telix has...

Read more

ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

ASX, Clinical, News,

Telix today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation...

Read more

Telix Announces Executive Leadership Appointments

ASX, News,

Telix today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession...

Read more